165 related articles for article (PubMed ID: 2031601)
1. Importance of 6-mercaptopurine dose in lymphoblastic leukaemia.
Hale JP; Lilleyman JS
Arch Dis Child; 1991 Apr; 66(4):462-6. PubMed ID: 2031601
[TBL] [Abstract][Full Text] [Related]
2. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia.
Lilleyman JS; Lennard L
Lancet; 1994 May; 343(8907):1188-90. PubMed ID: 7909868
[TBL] [Abstract][Full Text] [Related]
3. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial.
Nielsen SN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Hjalgrim LL; Schmiegelow K
Lancet Oncol; 2017 Apr; 18(4):515-524. PubMed ID: 28258828
[TBL] [Abstract][Full Text] [Related]
4. Intraindividual variation in 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute lymphoblastic leukaemia.
Lafolie P; Hayder S; Björk O; Peterson C
Eur J Clin Pharmacol; 1991; 40(6):599-601. PubMed ID: 1884741
[TBL] [Abstract][Full Text] [Related]
5. Intracellular metabolites of mercaptopurine in children with lymphoblastic leukaemia: a possible indicator of non-compliance?
Lennard L; Welch J; Lilleyman JS
Br J Cancer; 1995 Oct; 72(4):1004-6. PubMed ID: 7547211
[TBL] [Abstract][Full Text] [Related]
6. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia.
Lennard L; Gibson BE; Nicole T; Lilleyman JS
Arch Dis Child; 1993 Nov; 69(5):577-9. PubMed ID: 8257179
[TBL] [Abstract][Full Text] [Related]
7. Childhood lymphoblastic leukaemia: sex difference in 6-mercaptopurine utilization.
Lilleyman JS; Lennard L; Rees CA; Morgan G; Maddocks JL
Br J Cancer; 1984 Jun; 49(6):703-7. PubMed ID: 6587901
[TBL] [Abstract][Full Text] [Related]
8. Mercaptopurine in childhood leukaemia: the effects of dose escalation on thioguanine nucleotide metabolites.
Lennard L; Welch J; Lilleyman JS
Br J Clin Pharmacol; 1996 Oct; 42(4):525-7. PubMed ID: 8904630
[TBL] [Abstract][Full Text] [Related]
9. Prognostic importance of myelosuppression during maintenance treatment of lymphoblastic leukaemia. Leukaemia in Childhood Working Party of the Medical Research Council.
Dolan G; Lilleyman JS; Richards SM
Arch Dis Child; 1989 Sep; 64(9):1231-4. PubMed ID: 2684039
[TBL] [Abstract][Full Text] [Related]
10. Fat body mass and pharmacokinetics of oral 6-mercaptopurine in children with acute lymphoblastic leukemia.
Zuccaro P; Guandalini S; Pacifici R; Pichini S; Di Martino L; Guiducci M; Giuliano M; Di Tullio MT; Pettoello Mantovani M
Ther Drug Monit; 1991 Jan; 13(1):37-41. PubMed ID: 2057989
[TBL] [Abstract][Full Text] [Related]
11. Extremely low dose of 6-mercaptopurine in a Chinese child with acute lymphoblastic leukaemia and multiple pharmacogenetic mutations.
Zhai XY; Zhou Y; Dong L; Nie AQ; Zhi LJ; Jacqz-Aigrain E; Wang TY; Wang L; Zhao W
J Clin Pharm Ther; 2021 Feb; 46(1):74-77. PubMed ID: 32893890
[TBL] [Abstract][Full Text] [Related]
12. Variable mercaptopurine metabolism in children with leukaemia: a problem of non-compliance?
Davies HA; Lennard L; Lilleyman JS
BMJ; 1993 May; 306(6887):1239-40. PubMed ID: 8499854
[No Abstract] [Full Text] [Related]
13. Individualized 6-mercaptopurine increments in consolidation treatment of childhood acute lymphoblastic leukemia: A NOPHO randomized controlled trial.
Tulstrup M; Frandsen TL; Abrahamsson J; Lund B; Vettenranta K; Jonsson OG; Marquart HVH; Albertsen BK; Heyman M; Schmiegelow K
Eur J Haematol; 2018 Jan; 100(1):53-60. PubMed ID: 28983968
[TBL] [Abstract][Full Text] [Related]
14. Effect of a Daily Text Messaging and Directly Supervised Therapy Intervention on Oral Mercaptopurine Adherence in Children With Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Bhatia S; Hageman L; Chen Y; Wong FL; McQuaid EL; Duncan C; Mascarenhas L; Freyer D; Mba N; Aristizabal P; Walterhouse D; Lew G; Kempert PH; Russell TB; McNall-Knapp RY; Jacobs S; Dang H; Raetz E; Relling MV; Landier W
JAMA Netw Open; 2020 Aug; 3(8):e2014205. PubMed ID: 32852553
[TBL] [Abstract][Full Text] [Related]
15. Profile of non-compliance in lymphoblastic leukaemia.
Lancaster D; Lennard L; Lilleyman JS
Arch Dis Child; 1997 Apr; 76(4):365-6. PubMed ID: 9166035
[TBL] [Abstract][Full Text] [Related]
16. 'Acceptability' of a new oral suspension formulation of mercaptopurine in children with acute lymphoblastic leukaemia.
Mulla H; Buck H; Price L; Parry A; Bell G; Skinner R
J Oncol Pharm Pract; 2016 Jun; 22(3):387-95. PubMed ID: 25837624
[TBL] [Abstract][Full Text] [Related]
17. 6-Mercaptopurine dose escalation and its effect on drug tolerance in childhood lymphoblastic leukaemia.
Welch JC; Lilleyman JS
Cancer Chemother Pharmacol; 1996; 38(1):113-6. PubMed ID: 8603445
[TBL] [Abstract][Full Text] [Related]
18. Continuing (maintenance) therapy in lymphoblastic leukaemia: lessons from MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia.
Chessells JM; Harrison G; Lilleyman JS; Bailey CC; Richards SM
Br J Haematol; 1997 Sep; 98(4):945-51. PubMed ID: 9326194
[TBL] [Abstract][Full Text] [Related]
19. Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia.
Koren G; Langevin AM; Olivieri N; Giesbrecht E; Zipursky A; Greenberg M
Am J Dis Child; 1990 Oct; 144(10):1135-7. PubMed ID: 2403095
[TBL] [Abstract][Full Text] [Related]
20. Why more 6-mercaptopurine?
Kamen BA
Semin Hematol; 1991 Jul; 28(3 Suppl 4):12-4. PubMed ID: 1780746
[No Abstract] [Full Text] [Related]
[Next] [New Search]
